Recursion Pharmaceuticals Inc. (RXRX): Price and Financial Metrics Recent IPO


Recursion Pharmaceuticals Inc. (RXRX): $26.81

2.55 (+10.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RXRX Stock Price Chart Interactive Chart >

Price chart for RXRX

RXRX Price/Volume Stats

Current price $26.81 52-week high $42.81
Prev. close $24.26 52-week low $17.80
Day low $24.13 Volume 3,063,600
Day high $27.38 Avg. volume 479,092
50-day MA $28.17 Dividend yield N/A
200-day MA $0.00 Market Cap 4.52B

Recursion Pharmaceuticals Inc. (RXRX) Company Bio


Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.


RXRX Latest News Stream


Event/Time News Detail
Loading, please wait...

RXRX Latest Social Stream


Loading social stream, please wait...

View Full RXRX Social Stream

Latest RXRX News From Around the Web

Below are the latest news stories about Recursion Pharmaceuticals Inc that investors may wish to consider to help them evaluate RXRX as an investment opportunity.

Recursion Reports Second Quarter 2021 Financials and Provides Business Updates

Recursion (Nasdaq: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, today reported financial results and business updates for its second quarter ending June 30, 2021.

Yahoo | August 13, 2021

What You Need To Know About Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Investor Composition

The big shareholder groups in Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) have power over the company. Generally...

Yahoo | July 16, 2021

Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD

Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced its formation of a Therapeutics Advisory Board (TAB), chaired by Joseph Miletich, MD, PhD. The TAB will guide Recursion's executive team and Board of Directors on the key challenge of developing medicines at scale from its tech-enabled drug discovery pipeline and bringing them to the pat

Yahoo | July 13, 2021

Recursion Opens Child Care Center to Support Employees

Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced the opening of its child care center, adjacent to Recursion's Salt Lake City headquarters.

Yahoo | July 12, 2021

Recursion Signs Lease With Vestar for an Additional 100,000 sf of Space at the Gateway in Downtown Salt Lake City

Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that it is doubling the size of its headquarters at The Gateway in downtown Salt Lake City, signing a new lease with Vestar for an additional 100,000 square feet. The Gateway is a mixed-use lifestyle and entertainment district, featuring 1.2 million square feet of retail, dining and offi

Yahoo | July 1, 2021

Read More 'RXRX' Stories Here

RXRX Price Returns

1-mo 35.06%
3-mo -28.35%
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7344 seconds.